GHK-Cu is a synthetic copper tripeptide complex referenced in peptide research literature and commonly examined in laboratory studies involving copper-binding peptides and molecular signaling
AY has given paid lectures and sat on advisory boards for the following companies with drugs used in affective and related disorders: Flow Neuroscience, Novartis, Roche, Janssen, Takeda, Noema pharma, Compass, Astrazenaca, Boehringer Ingelheim, Eli Lilly, LivaNova, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, Sage, Neurocentrx
In patients with advanced non-small cell lung cancer, subcutaneous amifostine (1000 mg), together with hematopoietic growth factors, may have contributed to a decrease in observed toxicity of combination therapy with docetaxel, gemcitabine, and liposomal doxorubicin (Patlakas 2005)
Erika Ercolani